Despite an increased postremission toxic mortality ( 3 years : 6.6 % v. 4.1 % ; HzR , 1.69 ; 95 % CI , 0.93 to 3.08 ; P = .09 ) , disease-free survival was better among GO recipients ( 3 years : 60.6 % v. 54.7 % ; HzR , 0.82 ; 95 % CI , 0.67 to 1.02 ; P = .07 ) .